Harpoon Therapeutics, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa)
Clinical trials sponsored by Harpoon Therapeutics, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa), explained in plain language.
-
New hope for Hard-to-Treat myeloma: early trial of HPN217 underway
Disease control OngoingThis early-stage study is testing a new drug called HPN217 (also known as MK-4002) in about 100 people whose multiple myeloma has returned or no longer responds to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body process…
Phase: PHASE1 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 17, 2026 03:29 UTC
-
New hope for hard-to-treat cancers: experimental drug targets DLL3
Disease control OngoingThis study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancer that has DLL3 protein. The goal is to find the safest dose and see how well the body handles it. About 232 adults will take part in th…
Phase: PHASE1, PHASE2 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC